Sickle cell disease and hematopoietic stem cell transplantation: donor expansion, gene-modified grafts and prenatal horizons.
Curative SCD therapies are converging on the same challenge: establishing durable healthy hematopoiesis with acceptable toxicity, and progress will depend on graft quality, safer niche creation, patient-centred outcomes and equitable delivery.
Giula Mackina, Panicos Shangaris
· Current opinion in hematolog... · 0 citations